Kabbani S S, Watkins M W, Holoch P A, Terrien E F, Sobel B E, Schneider D J
The University of Vermont, Burlington, VT, USA.
J Thromb Thrombolysis. 2001 Oct;12(2):171-6. doi: 10.1023/a:1012927606107.
Optimal anti-thrombotic therapy for acute coronary syndromes (ACS) should suppress pro-thrombotic activity at the site of plaque rupture. We sought to determine whether platelet reactivity is increased in blood in the immediate vicinity of a ruptured plaque and is apparent even when blood is obtained by sampling from a catheter placed proximal to the lesion.
Blood was obtained from a catheter placed in the aorta and from the same catheter after engaging the culprit coronary artery. Platelet reactivity was determined with the use of flow cytometry by surface expression of P-selectin.
In preliminary studies we demonstrated that a marker of thrombin activity, fibrinopeptide A, was similarly increased in blood taken from the coronary sinus and coronary arterial ostium of patients with ACS. Subsequently blood was obtained from the aorta and coronary arterial ostium through a coronary guide catheter for assessment of platelet reactivity in 23 subjects with ACS and 22 subjects with stable angina. The percentage of platelets expressing P-selectin in response to 0.2 microM adenosine diphosphate (ADP) was greater in coronary arterial samples from patients with ACS (aorta=6.1+/-1%, coronary artery=8.8+/-1.6%, p=0.02) compared with that in patients with stable symptoms (aorta=6.9+/-1.2, coronary artery=6.5+/-1.4, p=NS).
Coronary arterial blood obtained from the ostium through a coronary guide catheter can be used to determine whether thrombin activity and platelet reactivity are increased in the immediate vicinity of a ruptured atherosclerotic plaque. The simplicity of the approach developed should facilitate its use in future studies designed to determine the impact of optimal suppression of platelet reactivity and the pro-thrombotic state before coronary interventions on short- and long-term clinical outcomes.
急性冠状动脉综合征(ACS)的最佳抗栓治疗应抑制斑块破裂部位的促血栓形成活性。我们试图确定在破裂斑块紧邻区域的血液中血小板反应性是否增加,以及即使通过从病变近端放置的导管取样获取血液时这种增加是否明显。
从置于主动脉的导管以及进入罪犯冠状动脉后同一导管获取血液。通过流式细胞术检测血小板表面P-选择素的表达来确定血小板反应性。
在初步研究中,我们证明凝血酶活性标志物纤维蛋白肽A在ACS患者取自冠状窦和冠状动脉口的血液中同样升高。随后,通过冠状动脉引导导管从主动脉和冠状动脉口获取血液,以评估23例ACS患者和22例稳定型心绞痛患者的血小板反应性。与症状稳定的患者相比,ACS患者冠状动脉样本中对0.2微摩尔二磷酸腺苷(ADP)反应而表达P-选择素的血小板百分比更高(主动脉:6.1±1%,冠状动脉:8.8±1.6%,p=0.02),而症状稳定患者为(主动脉:6.9±1.2,冠状动脉:6.5±1.4,p=无显著性差异)。
通过冠状动脉引导导管从冠状动脉口获取的冠状动脉血液可用于确定在破裂动脉粥样硬化斑块紧邻区域凝血酶活性和血小板反应性是否增加。所开发方法的简便性应有助于其在未来研究中的应用,这些研究旨在确定冠状动脉介入术前最佳抑制血小板反应性和促血栓形成状态对短期和长期临床结局的影响。